Predictive value of the vitamin K epoxide reductase complex subunit 1 G-1639A and C1173T single nucleotide polymorphisms in retinal vein occlusion

Clinical and Experimental Ophthalmology

Volumn 40, Issue 7, 2012, Pages 743-748

  Ortak, Huseyin ^a   Söǧüt, Erkan ^a   Demir, Helin ^a   Ardagil, Aylin ^b   Benli, Ismail ^a   Sahin, Semsettin ^a  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b Medeniyet University   (Turkey)

Author keywords

Real time PCR; Retinal vein occlusion; VKORC1 polymorphism

Indexed keywords

FIBRINOGEN; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE;

ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE CONTROL STUDY; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE FREQUENCY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; PREDICTIVE VALUE; RETINA VEIN OCCLUSION; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL VEIN OCCLUSION; RISK FACTORS;

EID: 84867403709     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/j.1442-9071.2012.02780.x     Document Type: Article

References (25)

1. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008; 33: 111-31.
2. Lattanzio R, Torres Gimeno A, Battaglia Parodi M, Bandello F. Retinal vein occlusion: current treatment. Ophthalmologica 2011; 225: 135-43.
3. Frangieh GT, Green WR, Barraquer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol 1982; 100: 1132-40.
4. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009; 7: 301-4.
5. Wang Y, Zhang W, Zhang Y etal. VKORC1 haplotypes are associated with arterial vascular diseases (stroke, coronary heart disease, and aortic dissection). Circulation 2006; 113: 1615-21.
6. Stafford DW. The vitamin K cycle. J Thromb Haemost 2005; 3: 1873-8.
7. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
8. Rost S, Fregin A, Ivaskevicius V etal. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
9. Thapa R, Paudyal G, Bernstein PS. Demographic characteristics, patterns and risk factors for retinal vein occlusion in Nepal: a hospital-based case-control study. Clin Experiment Ophthalmol 2010; 38: 583-90.
10. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 1): S62-9.
11. Oldenburg J, Bevans CG, Müller CR, Watzka M. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle. Antioxid Redox Signal 2006; 8: 347-53.
12. Lacut K, Larramendy-Gozalo C, Le Gal G etal. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboembolism: results from the EDITH Study. J Thromb Haemost 2007; 5: 2020-4.
13. Pasmant E, de Beauvoir C, Plessier A, Labreuche J, Bezeaud A. VKORC1 and CYP2C9 genetic polymorphisms in hepatic or portal vein thrombosis. Thromb Res 2010; 126: 134-6.
14. D'Andrea G, D'Ambrosio RL, Di Perna P etal. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105: 645-9.
15. Quteineh L, Verstuyft C, Descot C etal. Vitamin K epoxide reductase (VKORC1) genetic polymorphism is associated to oral anticoagulant overdose. Thromb Haemost 2005; 94: 690-1.
16. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HRAC. 1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2: e312.
17. Mattes D, Weger M, Renner W, Cichocki L, Haas A. Role of angiotensin-converting enzyme insertion/deletion and plasminogen activator inhibitor-1 4G/5G gene polymorphisms in retinal vein occlusion. J Thromb Haemost 2005; 3: 2583-4.
18. Steinbrugger I, Haas A, Maier R etal. Analysis of inflammation- and atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Mol Vis 2009; 15: 609-18.
19. Tavridou A, Petridis I, Vasileiadis M etal. Association of VKORC1 -1639 G>A polymorphism with carotid intima-media thickness in type 2 diabetes mellitus. Diabetes Res Clin Pract 2011; 94: 236-41.
20. Teichert M, Visser LE, van Schaik RH etal. Vitamin K epoxide reductase complex subunit 1 (VKORC1) polymorphism and aortic calcification: the Rotterdam Study. Arterioscler Thromb Vasc Biol 2008; 28: 771-6.
21. Nakai K, Habano W, Nakai K etal. Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations. Life Sci 2005; 78: 107-11.
22. Nakai K, Tsuboi J, Okabayashi H etal. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 2007; 8: 713-19.
23. Miyagata Y, Nakai K, Sugiyama Y. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin. Int Heart J 2011; 52: 44-9.
24. Rogers S, McIntosh RL, Cheung N etal. International Eye Disease Consortium. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010; 117: 313-19.
25. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med 1998; 128: 737-40.